Alder Biopharmaceuticals Inc
NASDAQ NMS:ALDR
Score: Negative (30)
1 day at current score.
Downgraded from Neutral on February 2nd 2018
Summary
- This company ranked negatively compared to the Healthcare sector
- Bearish sentiment is moderate and increasing
Short interest | Neutral
Short interest is moderate for ALDR with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 31.
ETF/Index ownership | Neutral
ETF activity is neutral. Over the last one-month, outflows of investor capital in ETFs holding ALDR totaled $266 million.
PMI by IHS Markit | Neutral
According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however.
Credit default swap
CDS data is not available for this security.
Please send all inquiries related to the report to score@ihsmarkit.com.
Charts and report PDFs will only be available for 30 days after publishing.
This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.